furmonertinib + garsorasib

Furmonertinib + garsorasib is a combination therapy being developed by Elis Pharmaceutical Technology (Allist) for the treatment of solid tumors harboring KRAS G12C mutations. The combination consists of furmonertinib, a third-generation, irreversible epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, and garsorasib (also known as D-1553), a potent and selective small molecule inhibitor of the KRAS G12C mutant protein. The therapeutic rationale is based on the observation that EGFR signaling often mediates adaptive resistance to KRAS G12C inhibition; by simultaneously targeting both the KRAS G12C protein and the upstream EGFR pathway, the combination aims to achieve more profound and sustained inhibition of the MAPK signaling pathway. This approach is currently being evaluated in Phase 2 clinical trials for patients with KRAS G12C-mutant advanced solid tumors, including non-small cell lung cancer and colorectal cancer.

Other names

furmonertinib and garsorasib combinationAST2818 and D-1553 combinationAST-2818 and D-1553 combinationAST 2818 and D-1553 combinationKRAS G12C + EGFR combination